Roche Maps Out Its ‘Top Three In Obesity’ Ambition

 
• By Andrew McConaghie
  
The average GLP-1 agonist patient today has a high BMI of 39 - Roche believes the market can be expanded to those with much lower scores.

More from Strategy

More from Therapy Areas